Biosport Project

Other Cell Therapy products

Autologous Chondrocyte Implantation (Orthocell, Austrailia) offers a treatment for symptomatic defects of the articulating cartilage of the joints, predominately the knee and ankle.

Autologous Tenocyte Implantation (Orthocell, Austrailia) is a cellular therapeutic, tendon regeneration solution introduced by Orthocell into the market in March 2010. It involves regenerating a patient’s tendon cells to assist in the treatment of torn or damaged tendons common in shoulder, knee, ankle and elbow injuries.

CELLTRANS (Summit Medical, part of OrthoD) is a post-operative autologous blood collection and re-infusion device that provides the clinician with the facility to re-infuse post-operatively collected blood through a series of filtration steps. Filter options available include a fat reducing, leukodepleting filter and a 40 micron microaggregate reducing filter. Marketed for orthopaedic applications.

Cytori Cell Therapy is based on clinical grade Adipose-Derived Regenerative Cells (ADRCs). Adipose tissue is collected via liposuction and processed. These ‘regenerative cells’ include stem cells, endothelial progenitor cells, leukocytes, endothelial cells, and vascular smooth muscle cells. Cytori Therapeutics (USA) have initiated ACT-OA, a Phase IIA/B clinical trial in patients with osteoarthritis affecting the knees. Other clinical trials include applications such as anterior cruciate ligament repair, bone repair and meniscal repair.

The Harvest SmartPrep Multicellular Processing System (Harvest, USA) enables point-of-care capture of a range of autologous regenerative cells, including Adipose Tissue Concentrate (AdiPrep®), purified adipose concentrate for optimal structural grafting and use as a stem-cell-rich scaffold.

Orthokine/ Regenokine is a medical device for the production of an autologous conditioned serum injection containing anti-inflammatory cytokine antagonists and growth factors for the treatment of osteoarthritis and chronic knee pain. The device was approved in 2006 by the European Comission and a number of elite athletes have, reportedly, received treatment. However, it is not clear the extent to which the device continues to be sold or used.

PLacental eXpanded Cells (PLX) (Pluristem, Israel) are a cell therapy product derived from human placentas. The company define PLX 'as mesenchymal-like adherent stromal cells'. These cells secrete therapeutic proteins to facilitate healing of damaged tissues.They technology is being developed under the FDA, EMA, PEI, Israeli Ministry of Health, as well as Australian Regulatory Authorities and is currently in clinical trials for muscle injury. The outcome of this trial will indicate their sutability for treating sports injuries.

Stempeutron (Stempeutics Research, India) is a medical device in development for automated isolation of SVF (stromal vascular fraction) cells from the patient's own fat tissue at the point-of-care.

SurgWerks is a bioprocessing tool for harvesting, selection/purification, testing, and delivering a therapeutic dose of autologous bone marrow derived cells and proteins, being developed by Cesca Therapeutics (USA).

TRINITY Evolution by Orthofix (USA) is an allograft comprised of cancellous bone with viable osteogenic and osteoprogenitor cells retained within the matrix and a demineralized cortical bone component. 


Cesca Therapeutics (USA)

Cytori Therapeutics (USA)

Harvest (USA)

Orthofix (USA)

Orthocell (Austrailia)

Stempeutics Research (India)

Summit Medical, part of OrthoD (UK)

Pluristem (Israel)


Data were collected via an online survey of company websites, press releases and other related documents, Jan - June 2015. This information is a direct reflection of how the companies in question represent the products they sell, products in their pipeline, the therapeutic areas they are targeting and stage of development.